Agglomeration

Agglomeration describes the process wherein particles, proteins, or cells cluster together to form larger aggregates, often compromising product quality and therapeutic efficacy in biopharmaceutical manufacturing. This phenomenon can occur during various production stages, from cell culture and fermentation through formulation and storage, typically resulting from environmental stresses, protein instability, or suboptimal processing conditions. Agglomeration poses significant challenges for biologics manufacturers, as particle formation can trigger immune responses, reduce drug bioavailability, and fail regulatory specifications.

Controlling agglomeration requires sophisticated process understanding and advanced analytical characterisation throughout development and manufacturing. Factors influencing agglomeration include pH fluctuations, temperature variations, mechanical stress during pumping or filtration, and formulation excipients. The industry employs multiple analytical techniques, dynamic light scattering, analytical ultracentrifugation, and nanoparticle tracking analysis to detect and quantify agglomerated species at micro and nanoscale levels. Quality by Design (QbD) approaches help identify critical process parameters that minimise agglomeration risks while maintaining product stability. For therapeutic proteins, especially monoclonal antibodies and fusion proteins, preventing agglomeration directly impacts safety profiles and shelf life. As regulatory agencies increase scrutiny on product quality attributes, biopharmaceutical companies must implement robust control strategies that address agglomeration throughout the product lifecycle from early development through commercial manufacturing.